CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 80 enrolled
Drug / intervention
Ipilimumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04124601
NCT04124601Phase 2Completed
CompareCT.gov

Neoadjuvant CHemoradiotherapy With Sequential Ipilimumab and NivOlumab in RECtal Cancer (CHINOREC): a Prospective Randomized, Open-label, Multicenter, Phase II Clinical Trial

Johannes Laengle, MD, PhD·interventional·Posted Oct 11, 2019·Updated Apr 23, 2024

In Brief

A Phase 2 clinical trial evaluating Chemoradiotherapy, Ipilimumab, and 1 other intervention for Rectal Cancer. Completed, enrolled 80 participants across 5 sites.

Detailed Summary

This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab and nivolumab in rectal cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Cancer
CountriesAustria
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 11, 2019
Enrollment StartJun 1, 2020
Primary CompletionMar 15, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6.7 years ago

Interventions

Chemoradiotherapyradiation

Capecitabine tablet with fractionated radiotherapy

Ipilimumabdrug

Infusion

Nivolumabdrug

Infusion